Search Site
(R)-CrizotinibC-MET/ALK inhibitor,potent and ATP-competitve


Catalog No. BCC1284
Size Price Stock
10mM (in 1mL DMSO) $75.00 In stock
10mg $50.00 In stock
50mg $100.00 In stock
100mg $140.00 In stock
Related Products

Organizitions Citing Our Products recently


Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris

Quality Control of (R)-Crizotinib

Chemical structure



Cell experiment [1]:

Cell lines

LLC SP and MP cell lines

Preparation method

The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.

Reacting condition

12 h; IC50=21.3 nM (MP cells); cell survival rate of 50.0±0.6%=22.4 nM (SP cells)


The inhibitory effects of crizotinib on MP cells and SP cells were determined by colony formation assay. The IC50 value of crizotinib for MP cells was 21.3 nM. Of note, the SP cells showed no significant changes after crizotinib treatment. However, the SP cells showed a cell survival rate of 50.0±0.6% following a combined treatment of crizotinib (22.4 nM) and verapamil (500 µM), compared with 105.3±0.4% survival of SP cells treated with crizotinib (22.4 nM) alone. The growth curves obtained demonstrate that crizotinib inhibited the growth of SP and MP cells, and this inhibition was dependent on both concentration and time.

Animal experiment [1]:

Animal models

NU/NU nude mice

Dosage form

intratumoral injection


Tumorigenicity was examined using immune-deficient mice, into which SP or MP cells of LLC were subcutaneously transplanted. Nonsorted LLC cells formed xenografts in mice at 1x105 cells. Tumor size was significantly decreased in the crizotinib-treated LLC groups (225±29 mm3) compared to the untreated group (PBS: 834±41 mm3) by 40 days after treatment.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.


[1] Xia P, Gou W F, Zhao S, et al. Crizotinib may be used in lewis lung carcinoma: A novel use for crizotinib[J]. Oncology reports, 2013, 30(1): 139-148.

(R)-Crizotinib Dilution Calculator

Concentration (start)
Volume (start)
Concentration (final)
Volume (final)


(R)-Crizotinib Molarity Calculator



Chemical Properties of (R)-Crizotinib

Cas No. 877399-52-5 SDF Download SDF
Synonyms PF 02341066, PF 2341066
Chemical Name 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine
Standard InChI InChI=1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1
Formula C21H22Cl2FN5O M.Wt 450.34
Solubility Soluble to 10 mM in DMSO and to 100 mM in 2eq.HCl
Storage Store at +4°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other courier with RT , or blue ice upon request.

Preparing Stock Solutions of (R)-Crizotinib

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.2205 mL 11.1027 mL 22.2054 mL 44.4109 mL 55.5136 mL
5 mM 0.4441 mL 2.2205 mL 4.4411 mL 8.8822 mL 11.1027 mL
10 mM 0.2221 mL 1.1103 mL 2.2205 mL 4.4411 mL 5.5514 mL
50 mM 0.0444 mL 0.2221 mL 0.4441 mL 0.8882 mL 1.1103 mL
100 mM 0.0222 mL 0.111 mL 0.2221 mL 0.4441 mL 0.5551 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Research Update of (R)-Crizotinib

1. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Int J Cancer. 2014 Mar 15;134(6):1484-94. doi: 10.1002/ijc.28475. Epub 2013 Oct 3.
Crizotinib concentrations in plasma and brain are regulated by Abcb1 only if a non-saturating dose is applied. The co-administration of elacridar and crizotinib not only substantially increases crizotinib concentrations in plasma and brain but also promotes the delivery of crizotinib to the brain.
2. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ann Oncol. 2014 Feb;25(2):415-22. doi: 10.1093/annonc/mdt572.
Crizotinib, a drug approved for the treatment of ALK-positive NSCLC, has been investigated for its clinical benefits in crizotinib-treated patients who have developed PD.
4. Crizotinib may be used in Lewis lung carcinoma: a novel use for crizotinib. Oncol Rep. 2013 Jul;30(1):139-48. doi: 10.3892/or.2013.2424. Epub 2013 Apr 24.
Crizotinib is an inhibitor of ALK that has been approved by FDA for the treatment of locally advanced or metastatic ALK-positive NSCLC. Crizotinib also exhibited antitumor activity in LLC cell lines, where it induced apoptosis and G1 phase arrest in LLC MP cells; inhibited cell proliferation in LLC SP cells; suppressed tumor growth and angiogenesis in established xenografted tumors; and activated the Smad signaling pathway.

Background on (R)-Crizotinib

Crizotinib is a potent, ATP-competitive, small-molecule and orally available inhibitor of c-Met kinase with a Ki value of 4 nmol/L[1].

Crizotinib has shown to inhibit wild-type c-Met phosphorylation with a mean IC50 value of 11 nmol/L in multiple human endothelial and carcinoma cell lines. Crizotinib has been demonstrated to inhibit cell growth and induce apoptosis in human GTL-16 gastric carcinoma cells. Additionally, crizotinib could inhibit cell migration and invasion induced by HGF in human NCI-H441 lung cancer cells. Moreover, crizotinib has revealed to block cell scattering of MDCK [1].

Crizotinib has been indicated to suppress tumor growth in GTL-16, NCI-H441 NSCLC, Caki-1 RCC, U87MG glioblastoma or PC-3 prostate tumor xenograft mice [1].

[1] Zou HY1, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S, Koudriakova TB, Alton G, Cui JJ, Kung PP, Nambu MD, Los G, Bender SL,Mroczkowski B, Christensen JG. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 2007 May 1;67(9):4408-17.

References on (R)-Crizotinib

Metformin restores crizotinib sensitivity in crizotinib-resistant human lung cancer cells through inhibition of IGF1-R signaling pathway.[Pubmed: 27144340]

Despite the impressive efficacy of crizotinib for the treatment of ALK-positive non-small cell lung cancer, patients invariably develop therapeutic resistance. Suppression of the IGF-1R signaling pathway may abrogate this acquired mechanism of drug resistance to crizotinib. Metformin, a widely used antidiabetic agent, may reverse crizotinib resistance through inhibition of IGF-1R signaling.

Directly Binding Rather than Induced-Fit Dominated Binding Affinity Difference in (S)- and (R)-Crizotinib Bound MTH1.[Pubmed: 26764587]

As one of the most successful anticancer drugs, crizotinib is found to be efficient in the suppression of MTH1, a new therapeutic target for RAS-dependent cancers. Deep analysis shows that stereospecificity is prevalent in the binding of crizotinib to MTH1, where the target is more preferred to bind with the (S)-enantiomer of crizotinib. Surprisingly, very similar binding modes were found for the two enantiomers (Huber et al. Nature 2014, 508, 222-227), which puzzled us to ask a question as to why such a subtle structural variation could lead to so large of a binding affinity difference. Thereafter, by using advanced all-atom molecular dynamics simulations, we characterized the free energy surfaces of the binding/unbinding processes of the (S) and (R)-crizotinib enantiomers to/from MTH1. Interestingly, we found that rather than the induced-fit process, which is prevalent in drug selectivity and specificity (Wilson et al. Science 2015, 347, 882-886), the directly binding process has dominated impact on the binding affinity difference of the enantiomers, implying a common mechanism of stereoselectivity of enantiomers.

Co-delivery of Sildenafil (Viagra(®)) and Crizotinib for synergistic and improved anti-tumoral therapy.[Pubmed: 24623484]

Cancer multi-drug resistance is a major issue associated with current anti-tumoral therapeutics. In this work, Crizotinib an anti-tumoral drug approved for the treatment of non-small lung cancer in humans, and Sildenafil (Viagra(®)), were loaded into micellar carriers to evaluate the establishment of a possible synergistic anti-tumoral effect in breast cancer cells.

[Pharmacology profile of crizotinib (Xalkori(®)Capsules) and clinical findings on this drug].[Pubmed: 23391552]


(R)-Crizotinib,877399-52-5,PF 02341066, PF 2341066,Tyrosine Kinase/Adaptors,c-MET, supplier, inhibitor,Antagonist,Blocker,Modulator,Agonist, activators, activates, potent, BioCrick

Online Inquiry

Fill out the information below

* Required Fields